Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03168464
Recruitment Status : Recruiting
First Posted : May 30, 2017
Last Update Posted : September 6, 2019
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
NSCLC patients with metastatic disease who have failed at least one prior treatment and have a minimum of two metastatic lesions (at least one measurable), are eligible if they have an ECOG Performance Status of 0-1. Patients will receive on Day 1, ipilimumab (every 6 weeks) concurrently with radiation (6Gy x 5 fractions). Nivolumab (every 2 weeks) will be given in addition to ipilimumab on day 22.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Metastatic Drug: Ipilimumab and Radiation therapy Drug: Nivolumab Phase 1 Phase 2

Detailed Description:

NSCLC patients with metastatic disease who have failed at least one prior treatment and have a minimum of two metastatic lesions (at least one measurable), are eligible if they have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. Patients must be willing to undergo a required pre-treatment biopsy prior to enrolling onto the study.

Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.

Patients are re-imaged at Week 9 (day 70 ± 7) to evaluate for response (defined as an objective response by RECIST of the measurable metastatic sites outside the radiation field). This response will be evaluated assessing clinical and positron emission computed tomography (PET/CT) responses in the non-irradiated measurable metastatic sites using RECIST 1.1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Eligible patients will receive on Day 1 ipilimumab 3mg/kg concurrently with Radiation therapy (6GY x 5 fractions). On Day 22, patients will receive nivolumab 240mg (every 2 weeks) in addition to ipilimumab (1mg/kg). Patients will be evaluated for response at Day 70 (+/- 7 days) for progression.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Actual Study Start Date : October 9, 2017
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Immunotherapy + Radiation
Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Drug: Ipilimumab and Radiation therapy
Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Other Name: Yervoy

Drug: Nivolumab
On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Other Name: OPDIVO




Primary Outcome Measures :
  1. enhance overall response rate (ORR) to the combination of ipi/nivo in chemo-refractory NSCLC and double the ORR of ipi/RT, from 18% based on intent to treat to 36%. [ Time Frame: 3 years ]
    to enhance the ORR to the combination of Ipi/Nivo in chemo-refractory NSCLC by preceding it with a combination of Ipi/RT to convert the irradiated tumor into an in situ vaccine and to double the ORR of Ipi/RT, from 18% based on intent to treat to 36%.


Secondary Outcome Measures :
  1. changes in T-cell receptor (TCR) repertoire in peripheral blood are associated with response to treatment [ Time Frame: 4 years ]
    changes in T-cell receptor (TCR) repertoire in peripheral blood are associated with response to treatment

  2. serum markers IFN-b, CXCL11, sMICA, sMICB levels/changes associated with patients' response to the treatment. [ Time Frame: 4 years ]
    serum markers interferon-beta(IFN-B), C-X-C motif chemokine 11(CXCL11), soluble major histocompatibility complex class I-related chain A(sMICA), soluble major histocompatibility complex class I-related chain B (sMICB) levels/changes associated with patients' response to the treatment

  3. associations of overall response rate (ORR) with changes in the microbiome [ Time Frame: 4 years ]
    associations of ORR with changes in the microbiome

  4. progression free survival [ Time Frame: 4 years ]
    Patients will be followed for progression free survival.

  5. Patients' time to progression will be assessed in this study. [ Time Frame: 3 years ]
    Patients' time to progression will be assessed in this study.

  6. Patients' duration of response (DOR) will be assessed in this study. [ Time Frame: 3 years ]
    Patients' duration of response (DOR) will be assessed in this study.

  7. Overall survival (OS) [ Time Frame: 4 years ]
    Patients will be followed for overall survival.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand and the willingness to sign a written informed consent document;
  2. Histologic diagnosis of NSCLC;
  3. Any Kras or epidermal growth factor receptor (EGFR) status is permitted; Patients with an EGFR sensitizing mutation must have received an EGFR tyrosine kinase inhibitor (either erlotinib, gefitinib or afatinib) and patients with anaplastic lymphoma kinase (ALK) translocation must have received anti-ALK therapy.
  4. Patients must have at least two distinct measurable metastatic sites, with one of at least 1 cm or larger in its largest diameter. Patients may have additional non-measurable metastatic lesions (e.g., bone metastases);
  5. Patients must have prior treatment with at least one line of therapy for metastatic NSCLC. Any prior therapy is permitted except prior therapy with ipilimumab, other anti cytotoxic T-lymphocyte-associated protein (CTLA) agents or Checkpoint inhibitors;
  6. An interval of 2 weeks from last previous therapy is required;
  7. Patients must have recovered from the toxic effect(s) of the most recent anti-cancer treatment to NCI CTCAE Grade 1 or less (except alopecia).
  8. Patients must have adequate organ and marrow function as defined by initial laboratory tests:

    white blood cell (WBC) ≥ 2000/uL

    • absolute neutrophil count (ANC) ≥ 1.5/uL
    • Platelets ≥ 100 x 103/uL
    • Hemoglobin ≥ 9 g/dL
    • Creatinine ≤ 1.5 x upper limit of normal (ULN)
    • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present.
    • Bilirubin ≤ 1.5 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin ≤ 3.0 mg/dL;
  9. Performance status Eastern Cooperative Oncology Group (ECOG) 0-1 or Karnofsky > 70%;
  10. Men and women, ages > 18 years of age;
  11. Life expectancy > 3 months;
  12. Patients may have brain metastases if these are stable for at least 4 weeks and patients are not steroid dependent;
  13. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study.

    • WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL ]. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (hCG)) within 72 hours prior to the start of study medication.Men should use avoid impregnating women during study and for 7 mos after the study.

Exclusion Criteria:

  1. Patients having no lesions outside the field of radiation thus nullifying the ability to measure an abscopal effect;
  2. Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic auto immune disease (e.g., rheumatoid arthritis, progressive systemic sclerosis [scleroderma]), systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis];
  3. Patients with a history of symptomatic interstitial lung disease OR a history of (non-infectious) pneumonitis that required oral or IV steroids or current pneumonitis.
  4. Patients with active HIV infection Patients with Hepatitis B and Hepatitis C infection.
  5. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea;
  6. Concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids; Tyrosine Kinase inhibitors such as erlotinib;
  7. Prior therapy with ipilimumab or another anti-CTLA-4 antagonist;
  8. Women and men who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 5mos (women) or 7mos(men) weeks after cessation of study drug, or have a positive pregnancy test at baseline, or are pregnant or breastfeeding;
  9. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03168464


Contacts
Layout table for location contacts
Contact: Sharanya Chandrasekhar, M.S. 212-746-7277 shc2043@med.cornell.edu
Contact: Pragya Yadav, Ph.D. 212-746-2546 pry2003@med.cornell.edu

Locations
Layout table for location information
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Catherine Shu, M.D         
Contact: Taylor Hardy    212-3046347    th2575@cumc.columbia.edu   
Weill Medical College of Cornell University Recruiting
New York, New York, United States, 10065
Contact: Sharanya Chandrasekhar    212-746-7277    shc2043@med.cornell.edu   
Contact: Christina Castro, B.S.    212-746-2546    chc2071@med.cornell.edu   
Principal Investigator: Silvia C Formenti, M.D.         
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Silvia Formenti, M.D. Weill Cornell Medicine New York Prebyterian hospital

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT03168464    
Other Study ID Numbers: 1607017434
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: September 6, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents